Leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease


Foundation Medicine was a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offered a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aimed to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

In June 2018, Roche and Foundation Medicine signed a definitive agreement under which Roche will acquire the outstanding shares of Foundation Medicine’s common stock not already owned by Roche and its affiliates at a price of $137 per share in cash. This corresponded to a total transaction value of $2.4 billion on a fully diluted basis, and a total company value of $5.3 billion on a fully diluted basis.


Year Invested: 2010

Recent News

September 24, 2018
Foundation Medicine Introduces FoundationOne®Liquid, the Latest Advance in the Company’s Liquid Biopsy Test for Solid Tumors in Patients with Advanced Cancer

August 6, 2018
Foundation Medicine Publishes New Data in Nature Medicine Supporting Blood Tumor Mutational Burden (bTMB) as a Novel Predictor of Response to Cancer Immunotherapy

July 31, 2018
Roche Purchases Shares in Tender Offer for FMI

Read More News

Associated Team Members

Alexis Borisy
Partner

Neil Exter
Partner

Sarah Larson
Partner/Chief Human Resources Officer